Novo Nordisk's Pipeline Double-Header at ADA: Zenagamtide Data Impresses, CagriSema Under Scrutiny

Novo Nordisk presents Zenagamtide's strong Phase 2 results and CagriSema's Phase 3 weight loss miss at ADA, but stock remains under pressure amid pipeline concerns.

Novo Nordisk heads into the American Diabetes Association's Scientific Sessions in New Orleans this week carrying a heavy burden. The stock has lost about 40% over the past twelve months, hovering near €37.75, and the market is demanding that the pipeline deliver more than just hope. With 40 abstracts on the slate, the spotlight falls on two candidates: already-released Phase 2 data for Zenagamtide (Amycretin) and the long-awaited Phase 3 readout for CagriSema.

The Phase 2 results for Zenagamtide, presented at the conference, have drawn attention for their strength. Over 36 weeks in adults with type 2 diabetes, the highest 40 mg dose cut HbA1c by an average of 1.71 percentage points. Nearly 89% of participants in that group reached the clinically meaningful threshold of HbA1c below 7%. Weight loss was equally striking: patients on the 40 mg dose shed 14.6% of their body weight by week 36, positioning the drug as a serious contender in the next wave of obesity therapy. Novo Nordisk has confirmed that Phase 3 for Zenagamtide will begin in the second half of 2026, though first results are not expected before 2028.

Yet the stock has barely reacted, and much of the market's attention is fixed on CagriSema, the fixed-dose combination of a long-acting amylin analogue and semaglutide. In the head-to-head REDEFINE-4 study, CagriSema produced 23% weight loss after 84 weeks, falling short of Eli Lilly's Zepbound at 25.5%. That miss has left a blemish that diabetes data must now erase. The REIMAGINE Phase 3 programme in type 2 diabetes is the key test—William Blair has noted that investors will scrutinise these results more closely than the obesity data. Strong efficacy across different background therapies could restore confidence in the drug's broader profile.

The pipeline extends well beyond those two candidates. Novo Nordisk is showing additional semaglutide data across cardiovascular, renal, pulmonary, asthma, sleep apnoea and MASH indications. Two early-stage studies are also recruiting: one for NNC0497-0040 in obesity and diabetes, the other for NNC0113-5840. The company has been investing heavily in production capacity—a renovated facility in the Czech Republic came online in June, funded in part by a €500 million digital health and AI push aimed at cutting development timelines by 10% to 15%.

On the financial side, Novo Nordisk has been a buyer of its own stock. A share buyback programme of up to 15 billion Danish kroner over twelve months is under way, with an active tranche of up to 11.2 billion kroner in B-shares running through February 2027. Through the end of May, the company had repurchased 17,889,179 B-shares at an average price of 263.47 kroner, for a total volume of 4.71 billion kroner. That support has done little to stabilise the share price, which is down roughly 16% year to date from the €37.35 close last week and almost 41% below its level a year ago.

Analysts remain cautious. The 23-strong consensus on Wall Street gives an average 12-month target of $65.56 and a median rating of "Hold". The distribution reveals 18 holds, four buys and one sell. Goldman Sachs reiterated a neutral stance at the start of June. Technically, the stock sits 5.43% above its short-term moving average but 9.40% below the 200-day line—a picture of tentative recovery without conviction.

The ADA conference runs until 8 June, and Novo Nordisk will host an R&D investor event via live webcast on 7 June to contextualise the data. For a company that, according to TD Cowen, is projected to hold only 31% of the $150 billion GLP-1 market by 2030 versus Eli Lilly's 62%, the next few days are crucial. Zenagamtide has offered a glimpse of future potential. CagriSema must now prove it can win the present.